BCR inhibitor failure in CLL: An unmet need

Nitin Jain; Susan O'Brien

doi:10.1182/blood-2016-09-739664

BCR inhibitor failure in CLL: An unmet need

Nitin Jain, Susan O'Brien

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Abstract

In this issue of Blood, Mato et al report a retrospective cohort analysis of patients with chronic lymphocytic leukemia (CLL) who discontinued a kinase inhibitor (KI).¹ Drug toxicity was the main reason for treatment discontinuation. Approximately 50% of patients who discontinued a KI responded to a subsequent salvage therapy.

Original language	English (US)
Pages (from-to)	2193-2194
Number of pages	2
Journal	Blood
Volume	128
Issue number	18
DOIs	https://doi.org/10.1182/blood-2016-09-739664
State	Published - Nov 3 2016

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2016-09-739664

Cite this

@article{0b8b5f4c20a64ed4b270f2e9eb0991fc,

title = "BCR inhibitor failure in CLL: An unmet need",

abstract = "In this issue of Blood, Mato et al report a retrospective cohort analysis of patients with chronic lymphocytic leukemia (CLL) who discontinued a kinase inhibitor (KI).1 Drug toxicity was the main reason for treatment discontinuation. Approximately 50% of patients who discontinued a KI responded to a subsequent salvage therapy.",

author = "Nitin Jain and Susan O'Brien",

note = "Publisher Copyright: {\textcopyright} 2016 by The American Society of Hematology.",

year = "2016",

month = nov,

day = "3",

doi = "10.1182/blood-2016-09-739664",

language = "English (US)",

volume = "128",

pages = "2193--2194",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "18",

}

TY - JOUR

T1 - BCR inhibitor failure in CLL

T2 - An unmet need

AU - Jain, Nitin

AU - O'Brien, Susan

PY - 2016/11/3

Y1 - 2016/11/3

N2 - In this issue of Blood, Mato et al report a retrospective cohort analysis of patients with chronic lymphocytic leukemia (CLL) who discontinued a kinase inhibitor (KI).1 Drug toxicity was the main reason for treatment discontinuation. Approximately 50% of patients who discontinued a KI responded to a subsequent salvage therapy.

AB - In this issue of Blood, Mato et al report a retrospective cohort analysis of patients with chronic lymphocytic leukemia (CLL) who discontinued a kinase inhibitor (KI).1 Drug toxicity was the main reason for treatment discontinuation. Approximately 50% of patients who discontinued a KI responded to a subsequent salvage therapy.

UR - http://www.scopus.com/inward/record.url?scp=84994461938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994461938&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-09-739664

DO - 10.1182/blood-2016-09-739664

M3 - Comment/debate

C2 - 27811187

AN - SCOPUS:84994461938

SN - 0006-4971

VL - 128

SP - 2193

EP - 2194

JO - Blood

JF - Blood

IS - 18

ER -

BCR inhibitor failure in CLL: An unmet need

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this